Article detail · 2024
Treatment of Pneumocystis jirovecii Pneumonia with Caspofungin and Clindamycin: An HIV Patient and Literature Review
Flora Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Dergisi
- Year
- 2024
- ISSN
1300-932X- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
English (OpenAlex)
The first-line treatment for Pneumocystis jirovecii pneumonia (PCP) is trimethoprim-sulfamethoxazole (TMP-SMZ).However, some cases require alternative agents due to the side effects of TMP-SMZ.Treatment with TMP-SMZ was initiated in an HIV-positive patient with microbiologically confirmed PCP, who presented with acute renal failure on admission.On the third day of treatment, TMP-SMZ was discontinued due to worsening renal function.Subsequently, clindamycin was initiated in combination with caspofungin.Although caspofungin-based therapies were shown to be effective against Pneumocystis in animal models, clinical experience in humans is limited.The patient was treated successfully with clindamycin combined with caspofungin.
Topics
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV/AIDS drug development and treatment
- Tuberculosis Research and Epidemiology
Primary topic Pneumocystis jirovecii pneumonia detection and treatment